1 Yu H, Yuan Y, Shen H, et al. Hematopoietic stem cell exhaustion impacted by p18 INK4C and p21 Cip1/Waf1 in opposite manners. Blood, 2006, 107: 1200-1206
[2]
2 Yuan Y, Shen H, Franklin D S, et al. In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. Nat Cell Biol, 2004, 6: 436-442
[3]
3 Kovalev G I, Franklin D S, Coffield V M, et al. An important role of CDK inhibitor p18 (INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol, 2001, 167: 3285-3292
[4]
4 Yuan Y, Yu H, Boyer M J, et al. Hematopoietic stem cells are not the direct target of spontaneous leukemic transformation in p18(INK4C)-null reconstituted mice. Cancer Res, 2006, 66: 343-351
[5]
5 Hosokawa H, Tanaka T, Kato M, et al. Gata3/Ruvbl2 complex regulates T helper2 cell proliferation via repression of Cdkn2c expression. Proc Natl Acad Sci USA, 2013, 110: 18626-18631
[6]
6 Eguchi T, Itadani H, Shimomura T, et al. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines. Mol Cancer Ther, 2009, 8: 1460-1472
[7]
7 Pei X H, Bai F, Smith M D, et al. CDK inhibitor p18 (INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell, 2009, 15: 389-401
[8]
8 Abate A A, Pentimalli F, Esposito L, et al. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview. Expert Opin Inv Drug, 2013, 22: 895-906
[9]
9 Huang X, Di Liberto M, Jayabalan D, et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood, 2012, 120: 1095-1106
[10]
10 Kirsch M, Morz M, Pinzer T, et al. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Gene chromosome Cancer, 2009, 48: 143-154
[11]
11 Lindberg D, Akerstrom G, Westin G. Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function. Neoplasia, 2007, 9: 533-535
[12]
12 Morishita A, Masaki T, Yoshiji H, et al. Reduced expression of cell cycle regulator p18 (INK4C) in human hepatocellular carcinoma. Hepatology, 2004, 40: 677-686
[13]
13 Leone P E, Walker B A, Jenner M W, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res, 2008, 14: 6033-6041
[14]
14 Carpenter A C, Bosselut R. Decision checkpoints in the thymus. Nat Immunol, 2010, 11: 666-673
